❗Focal LVSI (<5) and no LVSI do not have the same Oncologic outcomes in stage I endometrioid endometrial cancer. From Christian Dagher presentation today at #ESGO2024. Treating them as a single risk category should be reconsidered. OncoAlert #gyncsm Nadeem R. Abu-Rustum Ane Gerda Z Eriksson MD PhD

La Familia translates across the pond! 🥰 #GirlPower dinner #SGO2024 SGO ESGO European Network of Young Gynae Oncologists Núria Agustí Garcia Beryl Manning-Geist, MD Sushmita Gordhandas

SGO Bridges - Impressive ground-breaking research career building initiative!

Thank you SGO Amanda Nickles Fader, MD and all the BRIDGES folks for clinical trials training AND lifelong friendships Michael Toboni Group 4 for life #SGOMtg

Feeling so mutual ❤️

Hold for my upcoming #SGOBRIDGES phase II trial that moves raf/mek/fak inhibition + hormonal blockade to the FRONT-LINE in low grade serous #ovariancancer Expected to start enrolling Memorial Sloan Kettering Cancer Center in the next few weeks 👍

Green is the new black 🍀🍀

Moving the needle on fertility preservation in #endometrialcancer : molecular data can refine our approach!

Amazing experience learning from and working with Claire Friedman MD Dmitriy Zamarin MD PhD — so much to still discover about the immune system and GYN cancer! Read all about our study in Nature Medicine

Excellent read by the talented Tiffany Sia MD!

My “out of office” starting off a little differently than anticipated… All is well and first vacation in a year begins NOW. Great flight crew support and medical kit Delta!

Thank you IJGC for featuring our study on caring for young patients with #endometrialcancer MSKCC Team Uterus

Podcast “debut” with IJGC on our work on ovarian preservation in patients with #endometrialcancer. Always a fun time with Pedro T Ramirez and Jenny Mueller MD

Thrilled to participate in the editorial process, learn from the greats David Cohn, MD, MBA and work to bring forward advancements in GYN cancer care!

Newly arrived Winship gynecologic oncologist Beryl Manning-Geist, MD, kicks off the next session with a talk on targeted and hormone therapy options for treating low-grade epithelial ovarian cancer. #DDHO2024

A wonderful gynecologic cancer session comes to a close with a panel discussion and patient case presentation with all of our speakers. #DDHO2024

Antibody drug conjugates are an exciting new therapy, but so far targeting folate receptor + ovarian cancer is limited to high grade. Here, we show that low grade ovarian cancers have the same % of folate receptor positivity. Next up: see if these treatments benefit patients!

Had a wonderful time joining Tufts ObGyn Residency Program on behalf of Emory Gyn Ob to kick off this year’s Tufts OB/GYN grand rounds and talking about #fertility in #endometrialcancer

Our newest editorial is out now—bravo to #SENECA investigators for their collaborative effort. Excited to see what we can do with this database to improve our clinical care!

Excited to be named an early career new investigator by NRG oncology! Can’t wait to bring more of these #clinicaltrials to our patients at Winship Cancer Institute of Emory University Emory Gyn Ob nrgoncology.org/Home/News/Post…